FABP5 Silencing in Doxorubicin-Resistant Breast Cancer

MCF-7 cells and MCF-7/ADR cells were purchased from Nanjing KeyGen. Cells were maintained in RPMI-1640 media supplemented with 10% fetal bovine serum (ExCell Bio, Uruguay) and 1% penicillin/streptomycin at 37°C in a humidified 5% CO₂ atmosphere. MCF-7/ADR cells were cultivated in the presence of a low dose of doxorubicin hydrochloride (1 μg/mL, MCE, China) and passaged once in drug-free media before the tests to retain their resistance characteristic (Wang et al., 2016 (link)). MCF-7/ADR cells were transfected with FABP5-specific siRNA (sc-41237, Santa Cruz Biotechnology, USA) and control siRNA with 100 nM lipofectamine 3,000 reagents (L3000008, Invitrogen, USA) according to the instructions provided by the manufacturer. SBFI-26 (GC39236, GlpBio, USA), a FABP5 specific inhibitor, is used to suppress FABP5 expression. In 6 well plates, the cells were grown for observation. FABP5 expression was evaluated by qRT–PCR and WB technique 96 h after the transfection of cells (Lewuillon et al., 2022 (link)).